1. Show article details.

    New Analysis Finds UPLIZNA® (inebilizumab) Effective Among European Populations with Neuromyelitis Optica Spectrum Disorder (NMOSD)

    Business Wire – 12:30 PM ET 06/24/2022

    -- Data being presented at the European Academy of Neurology Congress demonstrates consistent reductions in NMOSD attacks and disability scores across populations -- Horizon Therapeutics plc (HZNP) today announced new findings from a post hoc analysis of the N-MOmentum Phase 3 pivotal trial of UPLIZNA supporting the medicine’s efficacy in Europeans living with NMOSD.

  2. Show article details.

    Horizon Therapeutics plc Submits Regulatory Filing for UPLIZNA® (inebilizumab) in Brazil

    Business Wire – 8:30 AM ET 06/15/2022

    Horizon Therapeutics plc (HZNP) today announced that it has submitted a regulatory filing to the Brazil National Health Surveillance Agency for UPLIZNA for the treatment of adult patients with anti-aquaporin-4 immunoglobulin G seropositive neuromyelitis optica spectrum disorder.

  3. Show article details.

    Horizon Therapeutics plc Named One of the Fortune Best Workplaces in Chicago™

    Business Wire – 7:45 AM ET 06/15/2022

    Horizon Therapeutics plc (HZNP) today announced that it has been named to the Fortune Best Workplaces in Chicago 2022 list, ranking No. 3 in the large company category.

  4. Show article details.

    Analyst Ratings for Horizon Therapeutics

    Benzinga – 11:05 AM ET 06/14/2022

    Horizon Therapeutics has observed the following analyst ratings within the last quarter: These 4 analysts have an average price target of $116.0 versus the current price of Horizon Therapeutics at $82.1, implying upside. Below is a summary of how these 4 analysts rated Horizon Therapeutics over the past 3 months.

  5. Show article details.

    Benzinga's Top Ratings Upgrades, Downgrades For June 14, 2022

    Benzinga – 10:03 AM ET 06/14/2022

    Evercore ISI Group upgraded the previous rating for US Silica Holdings Inc from In-Line to Outperform. According to B of A Securities, the prior rating for Tractor Supply Co was changed from Neutral to Buy. For NetApp Inc, Deutsche Bank upgraded the previous rating of Hold to Buy. CIBC upgraded the previous rating for Thomson Reuters Corp from Neutral to Outperformer.

  6. Show article details.

    Stocks That Hit 52-Week Lows On Monday

    Benzinga – 12:18 PM ET 06/13/2022

      During Monday's trading, 1214 companies set new 52-week lows. On Monday, the following stocks broke to new 52-week lows: Be sure to monitor Benzinga for the news traders need!

  7. Show article details.

    Analysis of Pooled Data from TEPEZZA® (teprotumumab-trbw) Clinical Trials Reinforces Safety Profile in People with Thyroid Eye Disease (TED)

    Business Wire – 10:00 AM ET 06/11/2022

    -- Data presented at ENDO 2022 indicates low rates of hyperglycemic events were easily controlled, did not cause treatment disruption and were most often seen in patients with pre-existing diabetes -- -- A separate poster presentation examined response to TEPEZZA in patients who were mildly hypothyroid and found outcomes were consistent with those in the overall pooled population -- DUBLIN---- ...

  8. Show article details.

    Horizon Therapeutics plc Named a Top Company for Executive Women

    Business Wire – 8:00 AM ET 06/09/2022

    Horizon Therapeutics plc (HZNP) today announced that it has been recognized by Seramount as a Top 75 Company for Executive Women. Seramount’s list focuses on women in the corporate officer and profit-and-loss leadership ranks.

  9. Show article details.

    Horizon Therapeutics plc to Present at the Goldman Sachs 43rd Annual Global Health Care Conference

    Business Wire – 4:30 PM ET 06/06/2022

    Horizon Therapeutics plc (HZNP) today announced that the Company will participate in the following conference in June: Goldman Sachs 43rd Annual Global Health Care Conference The conference presentation will be webcast live and may be accessed by visiting Horizon's website at http://ir.horizontherapeutics.com. A replay of the webcast will be available for one year following the event.

  10. Show article details.

    Horizon Therapeutics plc to Highlight Data and Education on Thyroid Eye Disease (TED) at the Endocrine Society (ENDO) 2022 Annual Conference

    Business Wire – 8:00 AM ET 06/02/2022

    -- Poster presentation will share results from the Phase 2 and Phase 3 trials on blood glucose levels in patients with Thyroid Eye Disease -- -- Three-time Olympic gold medalist Gail Devers will discuss her experience living with Graves’ disease and TED at events on Saturday, June 11 and Sunday, June 12 -- DUBLIN---- Horizon Therapeutics plc (HZNP) today announced new data will be presented at the E...

  11. Show article details.

    Data Presented from the MIRROR Randomized Controlled Trial Demonstrate KRYSTEXXA® (pegloticase injection) Plus Methotrexate Resulted in Significant Improvement in Efficacy and Safety (Infusion Reactions) Compared to KRYSTEXXA Monotherapy

    Business Wire – 8:00 AM ET 06/01/2022

    -- Data through Month 6 showed a greater than 32% increase in patient response rate and infusion reactions were reduced from 31% to 4% -- -- Oral presentation on MIRROR randomized controlled trial to be held at The EULAR 2022 European Congress of Rheumatology on June 2, 2022 at 11:35 a.m. CEST -- -- In March, the FDA granted priority review for the supplemental Biologic License Application of K...

  12. Show article details.

    Horizon Therapeutics plc Wins 2022 International CSR Excellence Award for #RAREis Adoption Fund

    Business Wire – 4:01 PM ET 05/31/2022

    Horizon Therapeutics plc (HZNP) today announced the company has won an International Corporate Social Responsibility Excellence Award for its partnership with Gift of Adoption to co-create the #RAREis Adoption Fund. Horizon partners with Gift of Adoption to support children with rare diseases who are adopted from orphanages around the world so they can thrive with their new families.

  13. Show article details.

    Attention Biotech Investors: Mark Your Calendar For These June PDUFA Dates

    Benzinga – 3:42 PM ET 05/31/2022

    May turned out to be a month of mixed fortunes as far as regulatory reviews are concerned. Among the companies that received the FDA's greenlight were Phathom Pharmaceuticals, Inc. , Bristol-Myers Squibb Company and Novartis AG . On the other hand, Verrica Pharmaceuticals Inc.'s viral skin infection treatment candidate was rejected by the regulator for the third time.

  14. Show article details.

    Analysis from the Phase 3 N-MOmentum Study Demonstrates the Effectiveness of UPLIZNA® (inebilizumab-cdon) Among Neuromyelitis Optica Spectrum Disorder Patients with Genetic Variations

    Business Wire – 8:00 AM ET 05/31/2022

    -- Data being presented at the CMSC Annual Meeting demonstrates UPLIZNA may reduce attack risk and disability among populations with genetic variables typically linked to poor treatment response -- Horizon Therapeutics plc (HZNP) today announced data from the Phase 3 pivotal trial of UPLIZNA in NMOSD illustrating the treatment’s effectiveness among patients with different genetic make-ups, including...

  15. Show article details.

    The Week Ahead In Biotech (May 30-June 4): FDA Decision For Eton's Partnered Epilepsy Drug, ASCO Conference Gets Underway And More

    Benzinga – 2:03 PM ET 05/30/2022

    Biotech stocks advanced in the week ended May 27, tracking the overall positive sentiment of the broader market. Among notable developments, Genocea Biosciences, Inc.  announced that it is shuttering operations amid a cash crunch. Verrica Pharmaceuticals, Inc.  suffered a setback after its viral skin infection treatment candidate was rejected by the Food and Drug Administration on its third try.

  16. Show article details.

    Benzinga's Top Ratings Upgrades, Downgrades For May 24, 2022

    Benzinga – 10:04 AM ET 05/24/2022

    Susquehanna upgraded the previous rating for Lattice Semiconductor Corp from Neutral to Positive. According to Barclays, the prior rating for Otis Worldwide Corp was changed from Equal-Weight to Overweight. B of A Securities upgraded the previous rating for Northwest Natural Holding Co from Underperform to Neutral.

  17. Show article details.

    Horizon Therapeutics plc to Present MIRROR Randomized Controlled Trial Primary Endpoint Data at The EULAR 2022 European Congress of Rheumatology

    Business Wire – 8:00 AM ET 05/24/2022

    -- Oral presentation on KRYSTEXXA® plus methotrexate to be held June 2, 2022 at 11:35 a.m. CEST-- -- Additional data presentations provide new insights on psychosocial and comorbidity impact of gout to help inform evolving treatment strategies -- DUBLIN---- Horizon Therapeutics plc (HZNP) today announced a series of data presentations during The EULAR 2022 European Congress of Rheumatology, June 1 – 4...

  18. Show article details.

    Benzinga's Top Ratings Upgrades, Downgrades For May 23, 2022

    Benzinga – 10:33 AM ET 05/23/2022

      See all analyst ratings upgrades.   See all analyst ratings downgrades.   See all analyst ratings initiations.

  19. Show article details.

    4 Analysts Have This to Say About Horizon Therapeutics

    Benzinga – 9:05 AM ET 05/23/2022

    Horizon Therapeutics has observed the following analyst ratings within the last quarter: These 4 analysts have an average price target of $127.5 versus the current price of Horizon Therapeutics at $90.35, implying upside. Below is a summary of how these 4 analysts rated Horizon Therapeutics over the past 3 months.

  20. Show article details.

    Horizon Therapeutics Earnings Perspective: Return On Capital Employed

    Benzinga – 9:52 AM ET 05/19/2022

    According to Benzinga Pro, during Q1, Horizon Therapeutics earned $204.26 million, a 17.95% increase from the preceding quarter. Return on Capital Employed is a measure of yearly pre-tax profit relative to capital employed by a business.

Page:

Today's and Upcoming Events

  • Aug
    03

    HZNP to announce Q2 earnings (Unconfirmed)

Past Events (last 90 days)

  • May
    04

    HZNP announced Q1 earnings.

Data provided by Thomson Reuters © 2022

Technical Events

Technical Analysis

PROVIDED BY TRADING CENTRAL
As with all your investments through Fidelity, you must make your own determination whether an investment is appropriate for you. Fidelity is not recommending or endorsing this security by making it available to customers. You should conduct research and perform a thorough investigation as to the characteristics of any securities you intend to purchase. Before investing, you should read the prospectus, offering circular, indenture, or similar document carefully for a full description of the product, including its features and risks, to determine whether it is an appropriate investment for your investment objectives, risk tolerance, financial situation and other individual factors, and be sure to re-evaluate those factors on a periodic basis.

Performance data shown represents past performance, which is no guarantee of future results. Current performance may be higher or lower than the performance data quoted. Yield and return will vary, therefore, you may have a gain or loss when you sell your shares.


Stock markets are volatile and can decline significantly in response to adverse issuer, political, regulatory, market, or economic developments. Growth stocks can be more volatile than other types of stocks. Value stocks can continue to be undervalued by the market for long periods of time. Foreign securities are subject to interest-rate, currency-exchange-rate, economic, and political risks, all of which are magnified in emerging markets. Illiquidity is an inherent risk associated with investing in real estate and REITs. There is no guarantee the issuer of a REIT will maintain the secondary market for its shares and redemptions may be at a price which is more or less than the original price paid. Closed-end funds can trade at a discount to their NAV. Shareholders of Master Limited Partnerships may be treated as partners for tax purposes. Partnerships issue a Schedule K-1 (Form 1065) rather than a Form 1099 form for tax purposes. It lists the partner's share of income, deductions, credits, etc. Speak with your tax advisor to determine how this may affect you. A royalty trust is a type of corporation, mostly in the United States or Canada, usually involved in oil and gas production or mining. Royalty trusts may have special tax treatment, so you should consult a tax advisor on the potential tax consequences of investing in them.

News, commentary and events are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.

Any data, charts and other information provided on this page are intended for research purposes to help self-directed investors evaluate many types of securities including, but not limited to common stocks, American Depository Receipts, Master Limited Partnerships, real estate investment trusts. traditional preferred stock, trust preferred securities, third-party trust certificates, convertible securities, mandatory convertible securities and other exchange-traded equity and/or debt securities. Criteria and inputs entered, including the choice to make security comparisons, are at the sole discretion of the user and are solely for the convenience of the user. Analyst opinions, ratings and reports are provided by third-parties unaffiliated with Fidelity. All information supplied or obtained from this page is for informational purposes only and should not be considered investment advice or guidance, an offer of or a solicitation of an offer to buy or sell a security, or a recommendation or endorsement by Fidelity of any security or investment strategy. Fidelity does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from its use.

462499.6.0
See the Latest Features
Personalized
Get relevant information about your holdings right when you need it.
See Your Performance Click the portfolio icon to get information about stocks you own without leaving the research page.
Faster Access to Positions A shortcut to view the full list of positions in your portfolio? Yes, please! Use the ticker search box.
Add Your Own Notes Use Notebook to save your investment ideas in one convenient, private, and secure place.
Convenient For You
Research that's clear, accessible, and all in one place makes for a better experience.
One-Stop Shop See everything you need to make investment decisions right in the dashboard.
Access Anywhere No matter where you are, use the Stock Research experience across multiple devices.
New Ideas, On the Ready Find new ideas using quick links to the Stock Screener.
New Ways to Research
Discover new tools to add or diversify your existing research strategy.
StockTwits Read live tweets from the financial and investing community about the stock you're interested in.
Fundamental Analysis Save time on research by getting an overall assessment of a company's valuation, quality, growth stability, and financial health.
Recognia Technical Analysis Perfect for the technical trader—this indicator captures a stock's technical events and converts them into short, medium, and long-term sentiment.
Top Competitors See how a stock measures up by instantly comparing it to the industry average and its top four competitors.
Social Sentiment Get a sense of people's overall feelings towards a company in social media with this summary tool.
Earnings Data Monitor earnings expectations over the past three quarters and model a stock's price based on its P/E.